AMERICAN THROMBOSIS AND HEMOSTASIS… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2006

Legal Domicile

Principal Officer

CRYSTAL WATSON

Phone

9145883550

Tax Period

2023-01-01 to 2023-12-31

AMERICAN THROMBOSIS AND HEMOSTASIS NETWORK INC, founded in 2006, is a mid-sized nonprofit in the Medical Research sector that reported $13.6M in total revenue in fiscal year 2023. Expenses of $16.4M exceeded revenue, resulting in a 21% operating deficit.

Mission

THE AMERICAN THROMBOSIS AND HEMOSTASIS NETWORK (ATHN) IS A NONPROFIT ORGANIZATION DEDICATED TO IMPROVING THE LIVES OF PEOPLE AFFECTED BY BLEEDING AND CLOTTING DISORDERS. WE'RE USING TECHNOLOGY TO SECURE DATA, ADVANCE KNOWLEDGE, TRANSFORM CARE--AND ULTIMATELY IMPROVE LIVES.

Program Service Accomplishments

Program 1

Expenses: $4,376,851

ATHN SYSTEMS:THIS PROGRAM COMPRISES THE SOFTWARE SYSTEMS AND CAPABILITIES REQUIRED AS A STEWARD OF A SECURE NATIONAL DATABASE USED TO SUPPORT CLINICAL OUTCOMES ANALYSIS, RESEARCH, AND PUBLIC HEALTH...

Program 2

Expenses: $4,066,902

COMMUNITY COUNTS CDC PUBLIC HEALTH SURVEILLANCE PROJECT (CDC):THIS FEDERAL PROJECT IS LED BY ATHN IN PARTNERSHIP WITH THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) AND THE U.S. HEMOPHILIA...

COMMUNITY COUNTS CDC PUBLIC HEALTH SURVEILLANCE PROJECT (CDC):THIS FEDERAL PROJECT IS LED BY ATHN IN PARTNERSHIP WITH THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) AND THE U.S. HEMOPHILIA TREATMENT CENTER NETWORK. ITS AIM IS TO COLLECT DATA ON PEOPLE WITH BLEEDING AND CLOTTING DISORDERS AND INCREASE KNOWLEDGE, MONITOR TRENDS, IDENTIFY RISK FACTORS, AND MORE. IN 2020, THE CDC RENEWED ATHN'S 5-YEAR COOPERATIVE AGREEMENT TO CONTINUE THE COMMUNITY COUNTS PROJECT AND:- STRENGTHEN COLLABORATION WITH TREATMENT CENTERS - CONTINUE DATA AND SPECIMEN COLLECTION AND TRANSFER- EVALUATE DATA QUALITY AND IMPROVEMENT- SHARE INFORMATION WITH THE COMMUNITYUSING ATHN SYSTEMS, OVER 453,000 SURVEILLANCE FORMS HAVE BEEN SUBMITTED TO CDC FOR MORE THAN 141,000 UNIQUE PATIENTS.

Program 3

Expenses: $3,536,429

ATHN RESEARCH PROGRAMS:ATHN, IN CONJUNCTION WITH OUR 140+ HEMOPHILIA TREATMENT CENTERS (HTCS) ACROSS THE UNITED STATES, LEADS OR SUPPORTS A NUMBER OF PROGRAMS THAT LEVERAGE OUR STAFF EXPERTISE AND...

ATHN RESEARCH PROGRAMS:ATHN, IN CONJUNCTION WITH OUR 140+ HEMOPHILIA TREATMENT CENTERS (HTCS) ACROSS THE UNITED STATES, LEADS OR SUPPORTS A NUMBER OF PROGRAMS THAT LEVERAGE OUR STAFF EXPERTISE AND INFRASTRUCTURE.OUR LEADING 2023 RESEARCH PROGRAMS INCLUDE:ATHN TRANSCENDS - THE WORLD'S LARGEST NATURAL HISTORY STUDY OF PEOPLE AFFECTED BY NON-NEOPLASTIC HEMATOLOGIC CONDITIONS, WAS CREATED IN RESPONSE TO THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE'S (NHLBI) BLUEPRINT FOR FACTOR VIII INHIBITOR CLINICAL TRIALS. WITH THE PRIMARY AIM OF DETERMINING THE SAFETY OF ALL THERAPIES UTILIZED IN THIS POPULATION.ATHN TRANSCENDS PLANS TO ENROLL PARTICIPANTS INTO VARIOUS COHORTS BASED ON DIAGNOSIS. ATHN TRANSCENDS' STUDY ARCHITECTURE IS DESIGNED TO ENCOURAGE THE CREATION OF MODULES EXPLORING SPECIFIC SAFETY AND EFFECTIVENESS ENDPOINTS. IN ADDITION, THE ATHN RESEARCH BIOREPOSITORY, LOCATED AT VERSITI, BLOOD CENTER OF WISCONSIN, WILL STORE BIOSPECIMENS FROM ATHN TRANSCENDS FOR FUTURE RESEARCH.ATHN TRANSCENDS IS ORGANIZED INTO SEVEN (7) COHORTS: 1. HEMOPHILIA 2. VON WILLEBRAND DISEASE 3. THROMBOSIS/THROMBOPHILIA4. NON-NEOPLASTIC HEMATOLOGIC CONDITIONS5. BLEEDING NOT OTHERWISE SPECIFIED (NOS) 6. RARE BLOOD DISORDERS7. CONGENITAL PLATELET DISORDERS

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $12,829,029

Program Service Revenue $0

Investment Income $740,677

Other Revenue $4,193

TOTAL REVENUE $13,573,899

Expense Breakdown

Grants Paid $4,715,723

Salaries & Benefits $8,029,734

Fundraising Expenses $0

Program Expenses $13,435,490

Other Expenses $3,688,164

TOTAL EXPENSES $16,433,621

Year-over-Year Comparison

	2023	2022	Change
Revenue	$13,573,899	$13,595,220	0.0%
Expenses	$16,433,621	$14,534,841	+0.1%
Net Income	$-2,859,722	$-939,621	+2.0%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$707,270

Total Directors

$6,000

Key Employees

$687,530

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
CHRISTOPHER E WALSH MD PHD	CHAIR	1.00	Officer Director	$0	$0	$0
TAMARA VOGEL MBA	TREASURER	1.00	Officer Director	$0	$0	$0
JIM MUNN RN MS	DIRECTOR	1.00	Director	$0	$0	$0
ROBERT SIDONIO MD	DIRECTOR	1.00	Director	$6,000	$0	$6,000
DUC BOBBY TRAN MD MSC	DIRECTOR	1.00	Director	$0	$0	$0
JENNIFER G DAVILA MD	DIRECTOR	1.00	Director	$0	$0	$0
TYLER BUCKNER MD MSC	DIRECTOR	1.00	Director	$0	$0	$0
EDITH ROSATO RPH IOM	DIRECTOR	1.00	Director	$0	$0	$0
MICHAEL NIEKAMP	CHIEF FINANCIAL OFFICER	40.00	Officer	$259,392	$55,377	$314,769
CRYSTAL WATSON	PRESIDENT AND CEO	40.00	Officer	$331,982	$60,519	$392,501
TAMMUELLA SINGLETON	CHIEF SCIENCE OFFICER	40.00	Key Emp	$354,733	$2,400	$357,133
MOSES MILES III	CHIEF OPERATING OFFICER	40.00	Key Emp	$294,021	$36,376	$330,397
SRIKANTH SUBRAMANYA	SENIOR DIRECTOR, ENGINEERING	40.00	Highest	$167,462	$73,650	$241,112
NABIL DAOUD	DIRECTOR, DATA SCIENCE	40.00	Highest	$178,254	$45,672	$223,926
LINDA MAGLIOCCO	VP, FINANCE AND ADMINISTRATION	40.00	Highest	$281,903	$68,854	$350,757
TROY VERBRUGGE	LEAD SOFTWARE ENGINEER	40.00	Highest	$190,458	$33,263	$223,721
CARRIE O'NEIL	DIRECTOR, RESEARCH PROGRAMS	40.00	Highest	$195,435	$29,356	$224,791

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$13,573,899	$16,433,621	$5,433,549	$-2,859,722
2022	$13,595,220	$14,534,841	$8,367,265	$-939,621
2021	$13,364,540	$13,560,977	$10,168,996	$-196,437
2020	$12,837,875	$13,160,458	$10,322,975	$-322,583
2019	$12,125,041	$12,505,599	$10,367,454	$-380,558
2018	$11,684,281	$11,592,038	$10,470,469	$92,243

AMERICAN THROMBOSIS AND HEMOSTASIS NETWORK INC